Skip to the beginning of the images gallery

Fludarabine phosphate - 99%, high purity , Ribonucleoside-diphosphate reductase RR1 inhibitor, CAS No.75607-67-9, Ribonucleoside-diphosphate reductase RR1 inhibitor

≥99%

CAS#: 75607-67-9
Formula: C₁₀H₁₃FN₅O₇P
Molecular Weight: 365.21
MDL number: MFCD00866418
PubChem CID: 30751

Item Number

F122999

Grouped product items
SKU	Size	Availability	Price
F122999-25mg	25mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$28.90
F122999-100mg	100mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$79.90
F122999-250mg	250mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$149.90
F122999-1g	1g	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$419.90

DNA synthesis inhibitor. Antitumor agent.

View related series

Cell Cycle/DNA Damage Nucleoside Antimetabolite/Analog Phosphorus compounds Six-Membered Heterocyclic Compounds

Basic Description

Synonyms	HMS2094O11 \| MLS004774150 \| SMR002544683 \| 2F-ara-AMP \| 2-Fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine \| Fludarabine for system suitability \| FLUDARABINE PHOSPHATE (USP-RS) \| Q185916 \| SR-05000001945-4 \| {[(2R,3S,4S,5R)-5-(6-AMINO-2-F
Specifications & Purity	≥99%
Biochemical and Physiological Mechanisms	Fludarabine represses DNA replication and suppresses the nucleotide metabolism by inhibiting the enzyme ribonucleotide reductase.DNA synthesis inhibitor. Antitumor agent. Interferes with ribonucleotide reductase and DNA polymerase as a purine analogue. Sh
Storage Temp	Store at 2-8°C,Argon charged
Shipped In	Wet ice
Action Type	INHIBITOR
Mechanism of action	Ribonucleoside-diphosphate reductase RR1 inhibitor
Note	Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description	Fludarabine is a purine analog included in the category of DNA-damaging drugs with well-known efficacy in B-cell chronic lymphocytic leukemia (B-CLL). Fludarabine Phosphate is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

Product Properties

ALogP	-3.1

Associated Targets(Human)

CA5A Tclin Carbonic anhydrase 5A, mitochondrial (1 Activities)

Discover Target: CA5A

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CA2 Tclin Carbonic anhydrase II (17698 Activities)

Discover Target: CA2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ESR1 Tclin Estrogen receptor alpha (17718 Activities)

Discover Target: ESR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NR3C1 Tclin Glucocorticoid receptor (14987 Activities)

Discover Target: NR3C1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PGR Tclin Progesterone receptor (8562 Activities)

Discover Target: PGR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)

Discover Target: ADRB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)

Discover Target: CHRM2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)

Discover Target: ADRB1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)

Discover Target: HTR1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)

Discover Target: ADRA2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AR Tclin Androgen Receptor (11781 Activities)

Discover Target: AR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)

Discover Target: CHRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD2 Tclin Dopamine D2 receptor (23596 Activities)

Discover Target: DRD2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)

Discover Target: GABRA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAOA Tclin Monoamine oxidase A (11911 Activities)

Discover Target: MAOA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)

Discover Target: CNR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD1 Tclin Dopamine D1 receptor (9720 Activities)

Discover Target: DRD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)

Discover Target: PTGS1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A2 Tclin Norepinephrine transporter (10102 Activities)

Discover Target: SLC6A2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH2 Tclin Histamine H2 receptor (5428 Activities)

Discover Target: HRH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAOB Tclin Monoamine oxidase B (8835 Activities)

Discover Target: MAOB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)

Discover Target: HTR2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)

Discover Target: HTR2C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)

Discover Target: AVPR2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA1 Tclin Adenosine A1 receptor (17603 Activities)

Discover Target: ADORA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)

Discover Target: AGTR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A4 Tclin Serotonin transporter (12625 Activities)

Discover Target: SLC6A4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)

Discover Target: ADRA1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)

Discover Target: PTGS2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH1 Tclin Histamine H1 receptor (7573 Activities)

Discover Target: HRH1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRM1 Tclin Mu opioid receptor (19785 Activities)

Discover Target: OPRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD3 Tclin Dopamine D3 receptor (14368 Activities)

Discover Target: DRD3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)

Discover Target: AVPR1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRD1 Tclin Delta opioid receptor (15096 Activities)

Discover Target: OPRD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRK1 Tclin Kappa opioid receptor (16155 Activities)

Discover Target: OPRK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)

Discover Target: HTR3A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A3 Tclin Dopamine transporter (10535 Activities)

Discover Target: SLC6A3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 Activities)

Discover Target: GRIN1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KCNH2 Tclin HERG (29587 Activities)

Discover Target: KCNH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CACNA1C Tclin Voltage-gated L-type calcium channel alpha-1C subunit (766 Activities)

Discover Target: CACNA1C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDE3A Tclin Phosphodiesterase 3A (3309 Activities)

Discover Target: PDE3A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 Activities)

Discover Target: SLC29A1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)

Discover Target: ADRA2B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2C Tclin Alpha-2c adrenergic receptor (4876 Activities)

Discover Target: ADRA2C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM3 Tclin Muscarinic acetylcholine receptor M3 (7750 Activities)

Discover Target: CHRM3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 Activities)

Discover Target: HTR2B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TBXA2R Tclin Thromboxane A2 receptor (5717 Activities)

Discover Target: TBXA2R

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA2A Tclin Adenosine A2a receptor (16305 Activities)

Discover Target: ADORA2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA3 Tchem Adenosine A3 receptor (15931 Activities)

Discover Target: ADORA3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

BDKRB2 Tclin Bradykinin B2 receptor (3970 Activities)

Discover Target: BDKRB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CA1 Tclin Carbonic anhydrase I (13240 Activities)

Discover Target: CA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Associated Targets(non-human)

Mc4r Melanocortin receptor 4 (1205 Activities)

Discover Target: Mc4r

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Npy1r Neuropeptide Y receptor type 1 (8 Activities)

Discover Target: Npy1r

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Cckar Cholecystokinin A receptor (90 Activities)

Discover Target: Cckar

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Pde4d Phosphodiesterase 4D (4 Activities)

Discover Target: Pde4d

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Hdac6 Histone deacetylase 6 (222 Activities)

Discover Target: Hdac6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mus musculus (284745 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Rattus norvegicus (775804 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

L1210 (27553 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rep Replicase polyprotein 1ab (378 Activities)

Discover Target: rep

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Names and Identifiers

IUPAC Name	[(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
INCHI	InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1
InChi Key	GIUYCYHIANZCFB-FJFJXFQQSA-N
Canonical SMILES	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N
Isomeric SMILES	C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N
WGK Germany	3
RTECS	UO7440900
PubChem CID	30751
Molecular Weight	365.21
Reaxy-Rn	8167686

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

7 results found

Lot Number	Certificate Type	Date	Item
D2418308	Certificate of Analysis	Mar 23, 2024	F122999
D2418309	Certificate of Analysis	Mar 23, 2024	F122999
D2418310	Certificate of Analysis	Mar 23, 2024	F122999
D2418323	Certificate of Analysis	Mar 23, 2024	F122999
D2418324	Certificate of Analysis	Mar 23, 2024	F122999
D2418325	Certificate of Analysis	Mar 23, 2024	F122999
I1524056	Certificate of Analysis	Jun 05, 2023	F122999

Chemical and Physical Properties

Solubility	Solubility in water: Practically Insoluble; Degree of Solubility in water: 8.9 g/l 20 °C; Very soluble in Dimethylformamide; Insoluble in Ether,Ethanol
Sensitivity	Hygroscopic
Specific Rotation[α]	12° (C=0.5,H2O)
Melt Point(°C)	203°C(dec.)(lit.)

Safety and Hazards(GHS)

Pictogram(s)	GHS08
Signal	Danger
Hazard Statements	H341:Suspected of causing genetic defects H372:Causes damage to organs through prolonged or repeated exposure H360:May damage fertility or the unborn child H350:May cause cancer H361:Suspected of damaging fertility or the unborn child
Precautionary Statements	P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P281:Use personal protective equipment as required. P270:Do not eat, drink or smoke when using this product. P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. P319:Get medical help if you feel unwell.
WGK Germany	3
RTECS	UO7440900
Reaxy-Rn	8167686
Merck Index	4126

References

1. W Plunkett,P Huang,V Gandhi. (1990-10-01) Metabolism and action of fludarabine phosphate.. Seminars in oncology, 17 ((5 Suppl 8)): (3-17). [PMID:1699280]
2. D D Von Hoff. (1990-10-01) Phase I clinical trials with fludarabine phosphate.. Seminars in oncology, 17 ((5 Suppl 8)): (33-38). [PMID:1699281]
3. H M Kantarjian,J R Redman,M J Keating. (1990-10-01) Fludarabine phosphate therapy in other lymphoid malignancies.. Seminars in oncology, 17 ((5 Suppl 8)): (66-70). [PMID:1699285]
4. G Rodriguez. (1994-01-01) Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.. Investigational new drugs, 12 ((2)): (75-92). [PMID:7532163]
5. L E Robertson,M J Keating. (1993-01-01) Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.. Cancer treatment and research, 64 (105-119). [PMID:7680874]
6. P McLaughlin,L E Robertson,M J Keating. (1996-01-01) Fludarabine phosphate in lymphoma: an important new therapeutic agent.. Cancer treatment and research, 85 (3-14). [PMID:9043771]
7. Sudipta Das,Claudette St Croix,Misty Good,Jie Chen,Jinming Zhao,Sanmei Hu,Mark Ross,Michael M Myerburg,Joseph M Pilewski,John Williams,Sally E Wenzel,Jay K Kolls,Anuradha Ray,Prabir Ray. (2020-06-25) Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy.. iScience, 23 ((7)): (101256-101256). [PMID:32580124]
8. M J Keating. (1990-10-01) Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.. Seminars in oncology, 17 ((5 Suppl 8)): (49-62). [PMID:1699283]
9. B D Cheson. (1990-10-01) Issues for the future development of fludarabine phosphate.. Seminars in oncology, 17 ((5 Suppl 8)): (71-78). [PMID:1699286]
10. H G Chun,B Leyland-Jones,B D Cheson. (1991-01-01) Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 ((1)): (175-188). [PMID:1702143]
11. Míriam Molina-Arcas,Beatriz Bellosillo,F Javier Casado,Emili Montserrat,Joan Gil,Dolors Colomer,Marçal Pastor-Anglada. (2002-11-02) Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.. Blood, 101 ((6)): (2328-2334). [PMID:12411296]
12. Francesca Ricci,Alessandra Tedeschi,Enrica Morra,Marco Montillo. (2009-05-14) Fludarabine in the treatment of chronic lymphocytic leukemia: a review.. Therapeutics and clinical risk management, 5 ((1)): (187-207). [PMID:19436622]
13. Julien Valton,Valérie Guyot,Alan Marechal,Jean-Marie Filhol,Alexandre Juillerat,Aymeric Duclert,Philippe Duchateau,Laurent Poirot. (2015-06-11) A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.. Molecular therapy : the journal of the American Society of Gene Therapy, 23 ((9)): (1507-1518). [PMID:26061646]
14. Andrea Celeghin,Silvia Giunco,Riccardo Freguja,Manuela Zangrossi,Silvia Nalio,Riccardo Dolcetti,Anita De Rossi. (2016-12-30) Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.. Cell death & disease, 7 ((12)): (e2562-e2562). [PMID:28032863]
15. Min Chen,Sheng Zhao,Wen-Huan Guo,Yi-Ping Zhu,Lei Pan,Zhi-Wen Xie,Wen-Lan Sun,Jun-Tao Jiang. (2020-08-19) Maternal exposure to Di-n-butyl phthalate (DBP) aggravate gestational diabetes mellitus via FoxM1 suppression by pSTAT1 signalling.. Ecotoxicology and environmental safety, 205 (111154-111154). [PMID:32810643]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Fludarabine phosphate - 99%, high purity , Ribonucleoside-diphosphate reductase RR1 inhibitor, CAS No.75607-67-9, Ribonucleoside-diphosphate reductase RR1 inhibitor

Basic Description

Product Properties

Associated Targets(Human)

Associated Targets(non-human)

Mechanisms of Action

Names and Identifiers

Certificates

Certificate of Analysis(COA)

Chemical and Physical Properties

Safety and Hazards(GHS)

Related Documents

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator